Bio-technology offers tremendous economic, medical and agricultural potential for India and is poised to take off the way Information Technology did 15 years ago. Undoubtedly, the biopharmaceutical industry is one of the fastest growing industries in the world and is responsible for generating many curative therapies.




 



BHS has charted out an aggressive research and development programme that will be supported by the extensive scientific talent of BioPharm Biologics and aimed at developing patented drugs for diseases with an unmet need. Innovation will help BHS to meet the challenges of the new patent laws in India.



Biocure’s focus products and services include:




 


There are countless diseases which have no therapy or at best poorly effective therapies.

BHS aims to bring a new generation of logically designed, generic biopharmaceutical drugs, developed through genetic engineering technology or gene cloning, to address this issue. BHS has identified 5 key drivers, which would help its customers and shareholders and arm it with a competitive positioning.





The company’s mission is to be the leader in the emerging generic biopharmaceutical drug business. It plans to achieve this by being the first company to launch several generic versions of biopharmaceutical drugs produced using genetic engineering methods.
 


BioPharm Biologics Inc is a pioneer in developing manufacturing techno-logies for producing generic versions of monoclonal antibody drugs.


The Company aims to become a serious player in contract manufacturing of biopharmaceuticals with its proposed initial 3% worldwide contract manufacturing capacity.

It is a research and development bio-technology company with an extensive scientific network and profound professional talent comprising prominent internationally recognized biomedical scientists.


















 

 Powered by